- Trials with a EudraCT protocol (444)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
444 result(s) found for: Activities of daily living.
Displaying page 1 of 23.
EudraCT Number: 2018-003426-89 | Sponsor Protocol Number: E2020-J081-345 | Start Date*: 2018-10-18 |
Sponsor Name:Eisai Co., Ltd. (Japan) | ||
Full Title: A Double-blind, Placebo-controlled Comparative Study and Open-label Extension Study to Confirm the Efficacy and Safety of E2020 in Subjects With Down Syndrome Having Regression Symptoms and Disable... | ||
Medical condition: Down syndrome, regression symptoms and disabled activities of daily living | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2006-000654-43 | Sponsor Protocol Number: MPC-7869-05-010.04 | Start Date*: 2006-07-31 |
Sponsor Name:Myriad Pharmaceuticals, Inc | ||
Full Title: Phase 3 Multinational, Randomized, Double Blind, Placebo Controlled Study of the Effect of Daily Treatment with MPC-7869 on Measures of Cognition, Activities of Daily Living and Global Function in ... | ||
Medical condition: Mild Dementia of the Alzheimer's Type | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) GB (Prematurely Ended) DE (Prematurely Ended) SE (Prematurely Ended) NL (Prematurely Ended) ES (Completed) DK (Completed) IT (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2015-001727-23 | Sponsor Protocol Number: HW01619 | Start Date*: 2015-06-05 |
Sponsor Name: | ||
Full Title: A Randomized, Double-Blind, Placebo- Controlled, Parallel-Group, Multi-Center Study to Assess the Efficacy of Once-Daily Fluticasone Propionate Aqueous Nasal Spray 200mcg for 14 Days on Ocular ... | ||
Medical condition: Ocular Symptoms Associated with Seasonal Allergic Rhinitis | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2004-000089-11 | Sponsor Protocol Number: AX-CL-09 | Start Date*: 2004-12-15 |
Sponsor Name:Axonyx Inc | ||
Full Title: A randomised, double-blind, placebo-controlled study to evaluate the safety and efficacy of two different doses of phenserine-tartrate in patients with probable mild to moderate Alzheimer’s disease | ||
Medical condition: Alzheimer's Disease is caused by a loss of nerve cells in the brain, particularly in the areas associated with memory and learning. The onset of Alzheimer's also affects the levels of a certain neu... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: HU (Completed) AT (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2017-002601-35 | Sponsor Protocol Number: ACT-2017-01 | Start Date*: 2018-07-02 |
Sponsor Name:PrimeCell Advanced Therapy a.s. | ||
Full Title: A Prospective, Randomized, Controlled, Multicenter, Phase II / III, Clinical Study to Evaluate the Effectiveness and Safety of NTC chondrograft® versus the Standard Procedure Arthroscopic Microfrac... | ||
Medical condition: Symptomatic knee articular cartilage defects | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: CZ (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2006-003479-11 | Sponsor Protocol Number: 06/Q2604/75 | Start Date*: 2007-05-22 |
Sponsor Name:North Staffordshire Combined Healthcare Trust | ||
Full Title: The Stroke Oxygen Study. A randomised controlled study of the benefits and risks of routine oxygen treatment after acute stroke | ||
Medical condition: Acute Stroke | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
EudraCT Number: 2008-002226-11 | Sponsor Protocol Number: SIMaMCI | Start Date*: 2008-10-07 |
Sponsor Name:Charité - Unversitätsmedizin Berlin | ||
Full Title: Randomized Controlled Trial of Simvastatin in Amnestic MCI Patients | ||
Medical condition: Amnestic mild cognitive impairment (MCI) denotes clinical conditions in the border zone between normal cognitive functioning and dementia. The definition of amnestic MCI by Petersen and his co-work... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2015-001850-13 | Sponsor Protocol Number: GLP-1/MCI | Start Date*: 2015-09-11 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERO-UNIVERSITARIA DI PARMA | |||||||||||||
Full Title: Long-acting exenatide: a tool to stop cognitive decline in patients with mild cognitive impairment with or without dysglycemia? | |||||||||||||
Medical condition: Moderate cognitive impairment | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-002373-12 | Sponsor Protocol Number: R&D:2008GR01 | Start Date*: 2008-10-02 | |||||||||||
Sponsor Name:University of Dundee | |||||||||||||
Full Title: Effect of Spironolactone on Exercise Capacity in functionally impaired older people without heart failure: a double blind placebo controlled trial | |||||||||||||
Medical condition: Older people with impairment in activities of daily living (sarcopenia) | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-005001-29 | Sponsor Protocol Number: ZEN-006-Z030 | Start Date*: 2006-05-09 |
Sponsor Name:Zentaris GmbH | ||
Full Title: Efficacy and safety of ozarelix acetate, a new GnRH antagonist in male patients with mild to moderate Alzheimer’s Disease (Regimen: 130 mg q4w, x3) | ||
Medical condition: Male patients with mild to moderate Alzheimer´ Disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male | |
Trial protocol: DE (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2021-001827-41 | Sponsor Protocol Number: PI2020_843_0094 | Start Date*: 2021-06-11 |
Sponsor Name:CHU Amiens-Picardie | ||
Full Title: Evaluation of the early use of norepinephrine in major abdominal surgery on postoperative organ dysfunction | ||
Medical condition: major abdominal surgery | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2017-001950-33 | Sponsor Protocol Number: 15/0592 | Start Date*: 2018-01-19 | |||||||||||
Sponsor Name:UCL | |||||||||||||
Full Title: Methylphenidate versus placebo for fatigue in advanced cancer (MePFAC) | |||||||||||||
Medical condition: Cancer-related fatigue | |||||||||||||
|
|||||||||||||
Population Age: | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-002701-11 | Sponsor Protocol Number: ACE | Start Date*: 2016-06-13 |
Sponsor Name:Oslo University Hospital | ||
Full Title: ADJUVANT CHEMOTHERAPY IN ELDERLY – GERIATRIC ASSESSMENT AND PROGNOSTIC GENE SIGNATURES | ||
Medical condition: undergone R0-resection of for colon cancer stage III | ||
Disease: | ||
Population Age: Elderly | Gender: Male, Female | |
Trial protocol: NO (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2004-000933-12 | Sponsor Protocol Number: AX-CL-10 | Start Date*: 2005-02-22 |
Sponsor Name:Axonyx Inc | ||
Full Title: A randomised, double-blind, placebo-controlled study to evaluate the safety and efficacy of two different doses of phenserine-tartrate in patients with probable mild to moderate Alzheimer’s disease | ||
Medical condition: Alzheimers disease is caused by a loss of nerve cells in the brain, particularly in the areas associated with memory and learning. The onset of Alzheimers's also affects the levels of a certain neu... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2015-004783-11 | Sponsor Protocol Number: 101SK202 | Start Date*: 2016-04-26 | |||||||||||
Sponsor Name:Biogen Idec Research Limited | |||||||||||||
Full Title: A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group, Dose-Ranging Study to Evaluate the Safety and Efficacy of Intravenous Natalizumab (BG00002) in Acute Ischemic Stroke | |||||||||||||
Medical condition: Acute Ischemic Stroke | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) DE (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-001172-36 | Sponsor Protocol Number: 2006/123 | Start Date*: 2007-08-16 | |||||||||||
Sponsor Name:King's College London | |||||||||||||
Full Title: Donepezil and Memantine in moderate to severe Alzheimer's Disease | |||||||||||||
Medical condition: Moderate to severe alzheimer's disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-004848-29 | Sponsor Protocol Number: NN6535-4730 | Start Date*: 2021-04-29 | |||||||||||
Sponsor Name:Novo Nordisk A/S | |||||||||||||
Full Title: A randomised double-blind placebo-controlled clinical trial investigating the effect and safety of oral semaglutide in subjects with early Alzheimer´s disease (EVOKE) | |||||||||||||
Medical condition: Mild cognitive impairment (MCI) or mild dementia, both of the Alzheimer’s type | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Trial now transitioned) CZ (Trial now transitioned) DE (Trial now transitioned) FI (Trial now transitioned) IE (Trial now transitioned) SK (Trial now transitioned) NL (Trial now transitioned) AT (Trial now transitioned) BE (Trial now transitioned) SI (Trial now transitioned) DK (Trial now transitioned) GR (Trial now transitioned) PL (Trial now transitioned) NO (Trial now transitioned) PT (Trial now transitioned) BG (Trial now transitioned) IT (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing) RO (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-004864-25 | Sponsor Protocol Number: NN6535-4725 | Start Date*: 2021-04-29 | |||||||||||
Sponsor Name:Novo Nordisk A/S | |||||||||||||
Full Title: A randomised double-blind placebo-controlled clinical trial investigating the effect and safety of oral semaglutide in subjects with early Alzheimer´s disease (EVOKE plus) | |||||||||||||
Medical condition: Mild cognitive impairment (MCI) or mild dementia, both of the Alzheimer’s type | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Trial now transitioned) CZ (Trial now transitioned) DE (Trial now transitioned) FI (Trial now transitioned) IE (Trial now transitioned) SK (Trial now transitioned) NL (Trial now transitioned) AT (Trial now transitioned) BE (Trial now transitioned) SI (Trial now transitioned) DK (Trial now transitioned) GR (Trial now transitioned) PL (Trial now transitioned) PT (Trial now transitioned) BG (Trial now transitioned) IT (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing) HR (Trial now transitioned) RO (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-000968-18 | Sponsor Protocol Number: MG0003 | Start Date*: 2019-09-06 | |||||||||||
Sponsor Name:UCB Biopharma SRL | |||||||||||||
Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis. | |||||||||||||
Medical condition: Generalized myasthenia gravis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) GB (GB - no longer in EU/EEA) PL (Completed) DE (Completed) HU (Completed) CZ (Completed) BE (Completed) ES (Restarted) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-002900-16 | Sponsor Protocol Number: CAFQ056A2203 | Start Date*: 2007-10-01 |
Sponsor Name:Novartis Pharma Services AG | ||
Full Title: A multi-centre, randomized, double-blind, placebo-controlled, parallel-group, multiple oral dose titration study in patients with Parkinson’s disease to assess the efficacy of AFQ056 in reducing L-... | ||
Medical condition: The main objective of this study is to assess the efficacy of AFQ056 in reducing L-dopa induced dyskinesias. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
